ArticleCurrent research in neurobiology2023
DREADD-mediated amygdala activation is sufficient to induce anxiety-like responses in young nonhuman primates.
Article in Current research in neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Overview of the DREADDs chemogenetics and the patent landscape of their actuators.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Integrating community Live Reviews into academic publishing: an exploratory study.Research integrity and peer review · 2026Article
- Noninvasive focal gene transfer of chemogenetic proteins in the primate brain.Cell reports methods · 2026Article
- Advances in chemogenetics: a review of DREADDs and its application in psychiatric disorders.Molecular psychiatry · 2026Review
- Article
- Transcriptomic diversity of amygdalar subdivisions across humans and nonhuman primates.Science advances · 2025Article
- Brainwide mesoscale functional networks revealed by focal infrared neural stimulation of the amygdala.National science review · 2025Article
- Insights into the Neurobiology of Behavioral Inhibition from Nonhuman Primate Models.Current topics in behavioral neurosciences · 2025Review
- An Honest Reckoning With the Amygdala and Mental Illness.The American journal of psychiatry · 2024Review
- Imaging-based chemogenetics for dissecting neural circuits in nonhuman primates.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2024Review
Corrections and comments
- Update of
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
Anxiety disorders are among the most prevalent psychiatric disorders, with symptoms often beginning early in life. To model the pathophysiology of human pathological anxiety, we utilized Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) in a nonhuman primate model of anxious temperament to selectively increase neuronal activity of the amygdala. Subjects included 10 young rhesus macaques; 5 received bilateral infusions of AAV5-hSyn-HA-hM3Dq into the dorsal amygdala, and 5 served as controls. Subjects underwent behavioral testing in the human intruder paradigm following clozapine or vehicle administration, prior to and following surgery. Behavioral results indicated that clozapine treatment post-surgery increased freezing across different threat-related contexts in hM3Dq subjects. This effect was again observed approximately 1.9 years following surgery, indicating the long-term functional capacity of DREADD-induced neuronal activation. [
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.